Skip to main content

OTCMKTS:TEAR - TearLab Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.06
▼ -0.0011 (-1.86%)
1 month | 3 months | 12 months
Get New TearLab Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TEAR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TEAR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for TearLab in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.06.

N/A

The current consensus among 0 polled investment analysts is to n/a stock in TearLab. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/18/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/15/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/15/2017HC WainwrightReiterated RatingBuy$4.00
i
Rating by Ram Selvaraju at HC Wainwright
5/16/2017HC WainwrightReiterated RatingBuy$4.00
i
Rating by Ram Selvaraju at HC Wainwright
5/16/2017Rodman & RenshawLower Price TargetBuy ➝ Buy$12.00 ➝ $4.00
i
3/12/2017HC WainwrightSet Price TargetBuy$12.00
i
Rating by Ram Selvaraju at HC Wainwright
3/11/2017Craig HallumSet Price TargetBuy$6.00
i
Rating by William Bonello at Craig Hallum
3/11/2017Feltl & Co.DowngradeStrong-Buy ➝ Buy$9.00
i
Rating by Ben Haynor at Feltl & Co.
3/10/2017Rodman & RenshawReiterated RatingBuy ➝ Buy$12.00
i
11/8/2016HC WainwrightSet Price TargetBuy$20.00
i
Rating by Ram Selvaraju at HC Wainwright
10/24/2016HC WainwrightSet Price TargetBuy$20.00
i
Rating by Ram Selvaraju at HC Wainwright
10/16/2016HC WainwrightReiterated RatingBuy$20.00
i
10/15/2016Rodman & RenshawReiterated RatingBuy$20.00
i
Rating by Ram Selvaraju at Rodman & Renshaw
8/5/2016Rodman & RenshawReiterated RatingBuy$20.00
i
Rating by Ram Selvaraju at Rodman & Renshaw
8/4/2016Roth CapitalDowngradeBuy ➝ Neutral
i
Rating by Chris Lewis at Roth Capital
7/12/2016Rodman & RenshawInitiated CoverageBuy$20.00
i
(Data available from 5/16/2016 forward)
TearLab logo
TearLab Corporation operates as an in-vitro diagnostic company in the United States and internationally. It offers TearLab Osmolority System, a proprietary in vitro diagnostic tear testing platform that measures tear film osmolarity for the diagnosis of dry eye disease; and enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. Its TearLab Osmolarity System consists of TearLab disposable, a single-use microfluidic microchip; TearLab pen, a hand-held device that interfaces with the TearLab disposable; and TearLab reader, a small desktop unit that allows for the docking of the TearLab pen, as well as provides a quantitative reading for the operator. The company was formerly known as OccuLogix, Inc. TearLab Corporation was founded in 1996 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $0.06
$0.06
$0.06

50 Day Range

MA: $0.06
$0.06
$0.06

52 Week Range

Now: $0.06
$0.02
$0.22

Volume

20,200 shs

Average Volume

97,724 shs

Market Capitalization

$727,281.90

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.74

Frequently Asked Questions

What sell-side analysts currently cover shares of TearLab?

The following sell-side analysts have issued research reports on TearLab in the last twelve months:
View the latest analyst ratings for TEAR.

What is the current price target for TearLab?

0 Wall Street analysts have set twelve-month price targets for TearLab in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for TearLab in the next year.
View the latest price targets for TEAR.

What is the current consensus analyst rating for TearLab?

TearLab currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TEAR.

What other companies compete with TearLab?

How do I contact TearLab's investor relations team?

TearLab's physical mailing address is 150 La Terraza Blvd. Suite 101, Escondido CA, 92025. The medical research company's listed phone number is 858-455-6006 and its investor relations email address is [email protected] The official website for TearLab is www.tearlab.com.